Search

Displaying results 2641 - 2650 of 10000 in total
  1. Drug

    INM005

    go.drugbank.com/drugs/DB16499
    Investigational

    INM005 was under investigation in clinical trials for the treatment of COVID-19. It was studied for pharmacokinetics, efficacy, and safety in a completed trial (NCT04494984). … Additionally, a retrospective cohort study investigated the effectiveness and safety of specific hyperimmune equine serum for severe hospitalized COVID-19 patients (NCT04954235)

    Categories: Experimental Unapproved Treatments for COVID-19
  2. Drug

    Deferoxamine

    go.drugbank.com/drugs/DB00746
    ApprovedInvestigational

    It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.

    Categories: Compounds used in a research, industrial, or household settingProducts: Desferal 500mg Powder for Solution for Injection, Deferoxamine Mesylate for Injection
  3. Drug

    Mupadolimab

    go.drugbank.com/drugs/DB16488
    Investigational

    NCT04464395 and NCT04734873 assessed its use for hospitalized COVID-19 patients alone or with standard care.

    Categories: Experimental Unapproved Treatments for COVID-19
  4. Drug

    Dronabinol

    go.drugbank.com/drugs/DB00470
    ApprovedIllicitInvestigational

    From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. … If not provided in their activated form (such as through synthetic forms like Dronabinol or [DB00486]), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A

    Synonyms: 3-Pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo(b,d)pyran-1-ol, 6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol
  5. Drug

    Tolrestat

    go.drugbank.com/drugs/DB02383
    ApprovedWithdrawn

    While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. … Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications.

  6. Drug

    Exagamglogene autotemcel

    go.drugbank.com/drugs/DB15572
    ApprovedInvestigational

    Sickle cell disease (SCD) is a genetic disorder characterized by the production of abnormal sickle-shaped red blood cells (called hemoglobin S, HbS) that initiate a pathophysiology resulting in severe … ] - a mainstay of treatment since the 1990s - as well as newer agents like [crizanlizumab] and [voxelotor].

    Synonyms: from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a
  7. Drug

    Aluminium monostearate

    go.drugbank.com/drugs/DB01375
    Experimental

    Aluminium monostearate is a salt of stearic acid and aluminium with the molecular formula Al(OH)2C18H35O2. … Also known as dihydroxyaluminium or dihydroxy(stearato)aluminium, it is used to form gels in the packaging of pharmaceuticals and in the preparation of colors for cosmetics.

  8. Drug

    Ammonium carbonate

    go.drugbank.com/drugs/DB15926
    ApprovedWithdrawn

    Mixtures: JACK Smelling Salts for Athletes and Eucalyptus Oil
  9. Drug

    Ancestim

    go.drugbank.com/drugs/DB09103
    ApprovedWithdrawn

    It was submitted to the FDA under the status of recommendation for approval with a 10 to 1 votes. … It is a 166 amino acid protein produced by E. coli with an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal

  10. Drug

    NB-001

    go.drugbank.com/drugs/DB12716
    Investigational

    NB-001 has been investigated for the treatment of Recurrent Herpes Labialis.